TIGIT promotes CD8+T cells exhaustion and predicts poor prognosis of colorectal cancer
| Autor: | Xudong Zhu, Dongbing Ding, Yong Huang, Tianyun Lan, Hongbo Wei, Rongpu Liang, Tufeng Chen, Xiaofeng Yang, Jun Shao, Jianpei Liu, Zongheng Zheng, Bo Wei |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Cancer Research
medicine.diagnostic_test Colorectal cancer business.industry T cell Lymphocyte Immunology medicine.disease Flow cytometry 03 medical and health sciences 0302 clinical medicine medicine.anatomical_structure Oncology TIGIT Cancer research medicine Immunology and Allergy Cytotoxic T cell Receptor business CD8 030215 immunology |
| Zdroj: | Cancer Immunology, Immunotherapy. 70:2781-2793 |
| ISSN: | 1432-0851 0340-7004 |
| DOI: | 10.1007/s00262-021-02886-8 |
| Popis: | TIGIT is a lymphocyte surface receptor, which is mainly expressed on the surface of CD8+T cells. The role of TIGIT in colorectal cancer and its expression pattern in colorectal cancer infiltrating lymphocytes are still controversial. This study aimed at identifying the function of TIGIT in colorectal cancer. Patients with colorectal cancer showed significantly higher TIGIT+CD8+T cell infiltration in tumor tissues, metastases compared with paired PBMC and normal tissues through flow cytometry. TIGIT+CD8+T cells showed an exhausted phenotype and expressed low levels of killer cytokines IFN-γ, IL-2, TNF-α. In addition, more inhibitory receptors such as PD-1, LAG-3, and TIM-3 were expressed on the surface of TIGIT+CD8+T cells. TGF-β1 could promote the expression of TIGIT and inhibit CD8+T cell function in vitro. Moreover, the accumulation of TIGIT+T cells in tumors was associated with advanced disease, predicted early recurrence, and reduced survival rates in colorectal cancer patients. Our results indicate that TIGIT can be a biological marker for the prognosis of colorectal cancer, and TIGIT can be used as a potential target for treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink